Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study

Mahyari, Hanifeh Mirtavoos; Khosravi, Adnan; Mahyari, Zeinab Mirtavoos; Monfared, Zahra Esfahani; Khosravi, Negin

doi:10.5812/ircmj.16005

Cited by 3 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that Seshie and colleagues reported 25.5% Her-2/neu positivity in a retrospective analysis of breast cancer subtype done in Korle Bu Teaching Hospital, Ghana, West Africa [17]. Studies by Yau and co-workers [18] reported Her-2/neu expression of 21.0% in breast cancer cases seen in Hong Kong while Mahyari and colleagues [19] observed 38% among Iranian woman with early stage breast cancer. A comparative multicenter study that ensures a uniform protocol and minimal analytical variations would be necessary to explain the variations observed.…”

Section: Discussionmentioning

confidence: 99%

Her-2/neu overexpression in breast cancers in patients of West African extraction seen in Lagos state University Teaching hospital, Nigeria

Sanni

Popoola

Ibrahim

et al. 2019

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Introduction: Her-2/neu is one of the most important molecular markers of breast cancer. Overexpression of Her-2/neu as evaluated by immunohistochemistry is necessary in the management of breast cancers. This study was performed to determine the proportion of expression of the biomarker amongst breast cancer patients who presented in our 'one-stop breast cancer unit' using automated immunohistochemistry. Materials and methods: Automated immunohistochemical analysis of 107 newly diagnosed breast cancer patients was done for expression of Her-2/neu, between 1st April, 2016 and 30th September, 2018. The data was analyzed using SPSS version 25 for windows and Microsoft excel, 2013. Results: Her-2/neu was overexpressed in 30.1% patients, and it shows no correlation with age and histological grade of the disease. Conclusion: There is overexpression of Her-2/neu in our local setting, and this observation is very relevant to any therapeutic decisions and management of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Her-2/neu overexpression in breast cancers in patients of West African extraction seen in Lagos state University Teaching hospital, Nigeria

Sanni

Popoola

Ibrahim

et al. 2019

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…In the United States, approximately 5–10% of initial breast cancer diagnosis indicates metastatic breast cancer (MBC), which has increased relapse and mortality rates [ 3 ]. The occurrence of cancer is commonly linked to genetic code malfunctions, leading to abnormal expression of human epidermal growth factor receptor 2 (ERBB2), progesterone [ 4 ], oestrogen receptors [ 5 ], tumour protein P53 [ 6 ], and others.…”

Section: Introductionmentioning

confidence: 99%

Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells

Munisvaradass

Kumar

Govindasamy

et al. 2017

IJMS

View full text Add to dashboard Cite

Breast cancer is a common malignancy among women. The innate and adaptive immune responses failed to be activated owing to immune modulation in the tumour microenvironment. Decades of scientific study links the overexpression of human epidermal growth factor receptor 2 (ERBB2) antigen with aggressive tumours. The Chimeric Antigen Receptor (CAR) coding for specific tumour-associated antigens could initiate intrinsic T-cell signalling, inducing T-cell activation, and cytotoxic activity without the need for major histocompatibility complex recognition. This renders CAR as a potentially universal immunotherapeutic option. Herein, we aimed to establish CAR in CD3+ T-cells, isolated from human peripheral blood mononucleated cells that could subsequently target and induce apoptosis in the ERBB2 overexpressing human breast cancer cell line, SKBR3. Constructed CAR was inserted into a lentiviral plasmid containing a green fluorescent protein tag and produced as lentiviral particles that were used to transduce activated T-cells. Transduced CAR-T cells were then primed with SKBR3 cells to evaluate their functionality. Results showed increased apoptosis in SKBR3 cells co-cultured with CAR-T cells compared to the control (non–transduced T-cells). This study demonstrates that CAR introduction helps overcome the innate limitations of native T-cells leading to cancer cell apoptosis. We recommend future studies should focus on in vivo cytotoxicity of CAR-T cells against ERBB2 expressing tumours.

show abstract

First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases

et al. 2017

View full text Add to dashboard Cite

BackgroundBreast cancer is the most frequent malignancy among women in Eastern Morocco. In this paper, we provide the first report on molecular breast cancer subtypes in this region. This is the largest population–based study on breast cancer among Moroccan women.MethodsWe analyzed 2260 breast cancer cases diagnosed at the Hassan II Regional Oncology Center between October 2005 and December 2012. Clinico-pathological and therapeutic features were studied. Molecular subtypes were determined and their associations with the clinico-pathological characteristics of the tumors were examined.ResultsThe mean age at diagnosis was 48.7 years ±11.4. Invasive ductal carcinoma was the predominant histological type (77.1%), followed by lobular invasive carcinoma (15.3%). The mean size of breast tumors was 3.5 cm ± 1.96, and 84% of our patients are diagnosed with tumors of more than 2 cm. Histological grade II tumors were the most frequent (70.4%), followed by advanced histological grade (18%). Lymph node positive tumors were observed in 64.8% of cases and 29.3% of patients had distant metastasis. Most tumors were hormone receptor-positive (73%) and 28.6% were HER2 positive. 86.1% of patients with hormone receptor-positive breast cancer were given hormone therapy, while 68.9% of patients with HER2+ breast cancer received targeted therapy with Herceptin. Luminal A was the commonest molecular subtype, followed by Luminal B, Triple Negative and HER2. The highest prevalence of premenopausal patients was observed in Triple Negative subtype (72.2%), followed by HER2 (64.1%), Luminal B (62.2%), and Luminal A (55.1%). Luminal B subtype had a poorer prognosis than Luminal A. Compared with Triple Negative, HER2 subtype tend to spread more aggressively and is associated with poorer prognosis.ConclusionsUnlike Western countries, breast cancer occurs at an earlier age and is diagnosed at a more advanced stage in Eastern Morocco. In this region, hormone receptor-positive tumors are predominant and so the majority of breast cancer patients should benefit from hormone therapy. HER2 subtype presents an aggressive tendency, suggesting the importance of anti-HER2 therapy. This study will contribute in developing appropriate screening and cancer management strategies in Eastern Morocco.

show abstract

Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study

Cited by 3 publications

References 37 publications

Her-2/neu overexpression in breast cancers in patients of West African extraction seen in Lagos state University Teaching hospital, Nigeria

Her-2/neu overexpression in breast cancers in patients of West African extraction seen in Lagos state University Teaching hospital, Nigeria

Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells

First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases

Contact Info

Product

Resources

About